Dual blockade of the renin-angiotensinaldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy

Singapore Medical Journal

Volumn 51, Issue 2, 2010, Pages 151-156

  Tan, F ^a   Mukherjee, J J ^a   Lee, K O ^a   Lim, P ^a   Liew, C F ^b  

^a SARAWAK GENERAL HOSPITAL   (Malaysia)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

ACE inhibitor; Albuminuria; Angiotensin receptor blocker; Diabetic nephropathy; Reninangiotensin system

Indexed keywords

ALBUMIN; ENALAPRIL; LOSARTAN;

ADULT; ALBUMINURIA; ARTICLE; ASIAN; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOLOGICAL BLOCKING; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINE LEVEL;

AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; HUMANS; LOSARTAN; MALE; MIDDLE AGED;

EID: 77951263527     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-62.
2. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A metaanalysis of individual patient data. Ann Intern Med 2001; 134:370-9.
3. Ravid M, Lang R, Rachman R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996; 156:286-9.
4. Chan JC, Ko GT, Leung DH et al. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57:590-600.
5. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med 2001; 345:861-9.
6. Lewis EJ, Hunsicker LG, Clarke WR. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 2001; 345:851-60.
7. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000; 36:449-67.
8. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32:387-92.
9. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14:1738-47.
10. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002; 25:95-100.
11. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003; 26:2268-74.
12. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321:1440-4.
13. Cetinkaya R, Odabas AR, Selcuk Y. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes. Int J Clin Pract 2004; 58:432-5.
14. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003; 63:1874-80.
15. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001; 59:2282-9.
16. Song JH, Lee SW, Suh JH, et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 2003; 60:318-26.
17. Kim MJ, Song JH, Suh JH, Lee SW, Kim GA. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy. Yonsei Med J 2003; 44:463-72.
18. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med. 2007; 24:486-93.
19. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001; 345:910-2.
20. Barnett AH, Bain SC, Bouter P, et al. Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-61.
21. Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000; 58:762-9.
22. Fujisawa T, Ikegami H, Ono M, et al. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am J Hypertens 2005; 18:13-7.
23. Song JH, Cha SH, Lee HJ, et al. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. Nephrol Dial Transplant 2006; 21:683-9.
24. Imanishi M, Yoshioka K, Konishi Y, et al. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia 1999; 42:999-1005.
25. Andersen S, Blouch K, Bialek J, et al. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000; 58:2129-37.
26. Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002; 17:1413-8.
27. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002; 62:1020-5.
28. Jacobsen P, Rossing K, Parving HH. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Curr Opin Nephrol Hypertens 2004; 13:319-24.
29. Tomlinson B, Young RP, Chan JC, Chan TY, Critchley JA. Pharmacoepidemiology of ACE inhibitor-induced cough. Drug Saf 1997; 16:150-1.
30. Woo KS, Nicholls MG. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br J Clin Pharmacol 1995; 40:141-4.